DEALS: Shire shells out $2.6B for New River Pharmaceuticals


Shire shells out $2.6B for New River Pharmaceuticals


DEALS

WHO

WITH

WHAT

SCOOP

Shire

New River Pharmaceuticals

$2.6B buyout

The deal gives Shire the ADHD drug Vyvanse, which has been the subject of two approvable letters from the FDA and is likely to get fully cleared shortly.

Bristol-Myers Squibb

Adnexus

$240M development pact

Bristol-Myers Squibb has committed to give Adnexus $30 million over the next three years and up to $210 million in milestones for each product developed in a new collaboration on new cancer therapies.

Invitrogen

Avista Capital

$210 sale

Invitrogen is selling its pharmaceutical services division, BioReliance, to Avista Capital for $210 million.

Inspire Pharmaceuticals

InSite Vision's

$33M deal

Inspire Pharmaceuticals has licensed the U.S. and Canadian commercialization rights to InSite Vision anti-infective AzaSite.

Cepheid

Altana

$27M sale

Cepheid is buying Sweden's Sangtec Molecular Diagnostics from Altana for about $27 million in cash.

Optimer Pharma

Par Pharmaceuticals

$20M buy-back

Optimer agreed to pay Par $20 million for the buy-back of Difimicin, which is in Phase IIb/III in North America.

Pluristem

Stem Cell Innovations

Stock swap and licensing deal

The licensing agreement provides Stem Cell with certain rights to Pluristem's PLX I product and 3-D stem cell expansion capability, in exchange for an upfront fee of 23 million shares of Stem Cell's common stock, milestone payments and royalties.

Sartorius

Stedim Biosystems

Deal

Germany's Sartorius has struck a deal to combine its biotech division with Stedim Biosystems. Sartorius emerges as the majority owner of a combined company called Sartorius Stedim Biotechnology.

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.